Tachyon Therapeutics develops novel, selective compounds to improve the treatment of cancer.
Tachyon Therapeutics has raised $11.6M in total funding. The most recent round was Series A. The last funding was announced in March 2023.
Tachyon Therapeutics's investors include Khosla Ventures, Red Tree Venture Capital, California Institute for Regenerative Medicine, Veblen Ventures.
Tachyon Therapeutics is headquartered in San Francisco, United States.
Tachyon Therapeutics develops novel, selective compounds to improve the treatment of cancer.
Tachyon Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tachyon Therapeutics — Funding & Investors." VCBacked, March 1, 2023, https://www.vcbacked.co/company/tachyon-therapeutics. Accessed October 4, 2026.
VCBacked. (2023). Tachyon Therapeutics — Funding & Investors. Retrieved October 4, 2026, from https://www.vcbacked.co/company/tachyon-therapeutics
{{cite web |title=Tachyon Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tachyon-therapeutics |website=VCBacked |access-date=October 4, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated